Neurology: clinical-trial pipeline
41,215 neurology trials are in ClinicalTrials.gov and the EU CTIS portal; 10,170 are not yet finished and 749 of those are in phase 2/3 or 3. Source: Arcadium Data, data as of .
Open trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 7,597 |
| Phase 2 | 726 |
| Phase 3 | 621 |
| Phase 1 | 387 |
| Phase 4 | 318 |
| Phase 1/2 | 264 |
| Early phase 1 | 129 |
| Phase 2/3 | 128 |
Sponsors with the most open trials
Recently changed open trials
| Registry id | Title | Sponsor | Phase | Status | Countries |
|---|---|---|---|---|---|
| NCT06373211 | Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with… | Assistance Publique - Hôpitaux de Paris | Phase 2 | Recruiting | France |
| NCT06307431 | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). | Merck Sharp & Dohme LLC | Phase 2 | Active, not recruiting | Argentina, Australia, Canada, Chile +9 |
| NCT06185764 | A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | Vertex Pharmaceuticals Incorporated | Phase 1/2 | Active, not recruiting | Australia, Belgium, Canada, Germany +6 |
| NCT05704361 | A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous R… | Hoffmann-La Roche | Phase 1 | Active, not recruiting | Belgium, Canada, Germany, Spain +8 |
| NCT03523858 | A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis | Hoffmann-La Roche | Phase 3 | Active, not recruiting | United Arab Emirates, Bosnia & Herzegovina, Brazil, Canada +20 |
| NCT03100149 | A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Di… | Hoffmann-La Roche | Phase 2 | Active, not recruiting | Austria, Germany, Spain, France +1 |
| NCT06077760 | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Parti… | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Argentina, Australia, Belgium, Brazil +29 |
| NCT05816382 | A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions | Takeda | Phase 2/3 | Active, not recruiting | Austria, Australia, Belgium, Switzerland +11 |
| NCT05626855 | Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab | Scholar Rock, Inc. | Phase 3 | Active, not recruiting | Belgium, Germany, Spain, France +5 |
| NCT05541627 | A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease | AskBio France, SAS, a subsidiary of AskBio Inc. | Phase 1/2 | Active, not recruiting | France |
| NCT04938817 | Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3… | Merck Sharp & Dohme LLC | Phase 1/2 | Active, not recruiting | Austria, Australia, Canada, Switzerland +8 |
| 2022-502903-31-00 | A prospective multi-centric, randomised, double-dummy, double- blind, placebo-controlled 3-way Phase III stud… | Medice Arzneimittel Puetter GmbH & Co. KG | Phase 3 | Active, not recruiting | Germany |
| NCT06305767 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V94… | Merck Sharp & Dohme LLC | Phase 1/2 | Active, not recruiting | Australia, Canada, Chile, Colombia +11 |
| NCT05284747 | EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | Amgen | Phase 4 | Active, not recruiting | Brazil, Sweden, United States |
| NCT05164172 | A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine | H. Lundbeck A/S | Phase 3 | Recruiting | Argentina, Canada, Spain, United Kingdom +6 |
| NCT04995523 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC | AstraZeneca | Phase 1/2 | Active, not recruiting | Australia, Belgium, Brazil, China +12 |
| 2024-512514-18-00 | AMASCIS-02. ALOGENIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN ISCHEMIC STROKE. A PHASE IIB MULTICENTE… | Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz | Phase 2 | Active, not recruiting | Spain |
| 2023-509518-12-01 | An Open label, Safety Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardiv… | Adeptio Pharmaceuticals Limited | Phase 2 | Not yet recruiting | Czechia, Poland |
| 2023-507556-68-00 | A two-year, double-blind, randomized, multicenter, active controlled Core Phase study to evaluate the safety… | Novartis Pharma AG | Phase 3 | Active, not recruiting | Germany, Spain, France, Romania +1 |
| 2023-506998-35-00 | Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagno… | Vaestra Goetalandsregionen | Phase 3 | Recruiting | Austria, Denmark, Norway, Sweden |
All areas: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Neurology clinical trials: 10,170 open, 749 in phase 3", https://arcadiumdata.io/clinical-trials/area/neurology/, data as of 2026-10-25.